Novartis has agreed to acquire Avidity Biosciences, Inc., a biopharmaceutical company focusing on RNA therapeutics for genetic neuromuscular diseases. The acquisition will enhance Novartis’ neuroscience franchise, with three late-stage programs and a new delivery platform. The deal is valued at $12 billion in cash and is expected to close in the first half of 2026. Avidity’s innovative AOC platform is designed to treat diseases like myotonic dystrophy, facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy. This acquisition aligns with Novartis’ long-term strategy and aims to deliver groundbreaking RNA therapies for patients.

Read more at GlobeNewswire: Novartis agrees to acquire Avidity Biosciences, an